Skip to main content

Advertisement

Table 6 Demographic information of lymphocyte apoptosis studies

From: Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine

Author Age Gender (%male) Ethnicity Severity of subject disease Subject drug exposure documentation
Subjects Controls Statistical test result Subjects Controls Statistical test result Index Score No. of groups Sedatives Antibiotics Steroids
Roger [43] 63 (37 to 82) 55 (37 to 5) 0.04 50 43 0.76 N SAPS II 55 (12 to 92) 2 N Y t Y t
Bandyopadhyay [58] ? 'Matched’ N ? 'Matched’ N N APACHE >21 1 N N N
White [11] 54 (72 to 80) Bacteraemia: 73 (70 to 82) >0.05 52 Bacteraemia 40 >0.05 Y APACHE 25 (21 to 28) 2 N N N
White [11] 64 ± 2 65 ± 1 0.74 68 70 0.86 N    2 N N N
Zhang [44] 58 ± 4 59 ± 4 N 52 50 N N APACHE II 26 ± 3 1 N Y t Y t
Guignant [45] 63 (54 to 73) ? N 68 N N   SAPS II 53(39 to 64) 1 N N Y t
Vaki [46] 71 ± 2 ? N 54 ? N N APACHE II 20 ± 9 1 (3) N N N
Slotwinski [62] 62 ± 9; 63 ± 9 - N 5, 50 - N N TNM ? 1 N Y t N
Gogos [47] 67 ± 17; 68 ± 20; 54 ± 25; 64 ± 16   P < 0.0001 52, 62, 57, 67, 64   P = 0.011 N APACHE II 12 ± 7; 16 ± 9; 13 ± 8; 18 ± 8; 20 ± 5 3 N N N
Hoogerwerf [48] 57 ± 5, 66 ± 5 N* (p < 0.0001) 63 50 N N APACHE II 19 ± 2 1 N N N
Yousef [49] 44 ± 9 45 ± 9, 44 ± 10 N 59 60, 57 N N SOFA 12 (7 to 14) 3 (5) N N N
Turrel-Davin [50] 60 ± 4 'Age matched’ N 63 'Sex matched’ N N SAPS II 51 ± 3 1 N N Y
Pelekanou [51] 69 ± 16 64 ± 20 0.099 64 43 0.300 N APACHE II 18 ± 4; 15 ± 5 1 N N Y
Papadima [61] 66 ± 7; 67 ± 10   0.8 85, 47   0.54 N ASA I to II 1 Y t Y t Y t
Delogu [52] ? ? N ? ? N N ? ? 1 N N N
Weber [53] 56 ± 4 61 ± 5,? >0.05 68, 80 ? N N SAPS II 26 ± 2 1 N N Y
Roth [54] 56 ± 6 52 ± 14 N 66 'Matched’ N N APACHE N/S 1 N N N
Le Tulzo [55] 55 ± 4; 64 ± 4 72 ± 4; 55 ± 4 N* (p < 0.0001) ? ? N N SAPS II 33 ± 3; 58 ± 4 2 N N N
Hotchkiss [56] N/S N/S N 59 56, ? N N -   1 N N Y
Delogu [63] 47 ± 17 'Matched’ N ? 'Matched’ N N ASA I to II 1 Y N Y t
Pellegrini [59] 44 (20–83) (18 to 60) N ? ? N N ISS 25 (9 to 59) 1 N N N
Delogu [64] ? 'Matched’ N ? 'Matched’ N N ASA I to II 1 N N Y t
Hotchkiss [60] 18 to 46 ? N 90 ? N N ISS N/S (9 to 50) 1 N N N
Hotchkiss [57] N/S N/S N 65 ? N N -   1 N N Y
Sasajima [65] 62 (55 to 74); 49(37 to 58)   N   ? N N ? ? 1 N N N
Sugimoto [66] N/S   N 50   N N ? ? 1 N N Y t
  1. Age: N/S, not summarised (tabulated data for every patient provided); question mark (?), not provided within the manuscript; N/A, not applicable. Statistical test result: N, not reported; N*, not reported but we identified the significant p value from the original manuscript data. Severity of subject disease: The average clinical severity score of subjects with an index of spread listed in brackets. The number of severity groups which subjects were divided into is listed. ISS/AIS, Injury Severity Score/Abbreviated Injury Severity Score [87]; ASA, American Society of Anesthesiologists Physical Status Classification System [85]; APACHE II: Acute Physiology and Chronic Health Evaluation II [83], APACHE III, Acute Physiology and Chronic Health Evaluation III [84]. Subject drug use detailed: whether patient exposure to known immunomodulating drugs was documented. A‘t’ signifies that the timing of the drug administration in relation to blood sampling was clear from the study methodology.‘Matched’, paper provided no details but stated the control population was matched to the study population.